These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 7749862)

  • 1. Tissue factor pathway inhibitor activity in human plasma. Measurement of lipoprotein-associated and free forms in hyperlipidemia.
    Kokawa T; Abumiya T; Kimura T; Harada-Shiba M; Koh H; Tsushima M; Yamamoto A; Kato H
    Arterioscler Thromb Vasc Biol; 1995 Apr; 15(4):504-10. PubMed ID: 7749862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levels of factor VIIc associated with decreased tissue factor pathway inhibitor and increased plasminogen activator inhibitor-1 in dyslipidemias.
    Zitoun D; Bara L; Basdevant A; Samama MM
    Arterioscler Thromb Vasc Biol; 1996 Jan; 16(1):77-81. PubMed ID: 8548430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measurement of the free form of TFPI antigen in hyperlipidemia. Relationship between free and endothelial cell-associated forms of TFPI.
    Kokawa T; Enjyoji K; Kumeda K; Kamikubo Y; Harada-Shiba M; Koh H; Tsushima M; Yamamoto A; Kato H
    Arterioscler Thromb Vasc Biol; 1996 Jun; 16(6):802-8. PubMed ID: 8640408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue-factor pathway inhibitor and lipoproteins. Evidence for association with and regulation by LDL in human plasma.
    Hansen JB; Huseby NE; Sandset PM; Svensson B; Lyngmo V; Nordøy A
    Arterioscler Thromb; 1994 Feb; 14(2):223-9. PubMed ID: 8305412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue factor pathway inhibitor; its structure, function and clinical significance.
    Kato H
    Pol J Pharmacol; 1996; 48(1):67-72. PubMed ID: 9112630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response of plasma tissue factor pathway inhibitor to diet-induced hypercholesterolemia in crab-eating monkeys.
    Abumiya T; Nakamura S; Takenaka A; Takenaka O; Yoshikuni Y; Miyamoto S; Kimura T; Enjyoji K; Kato H
    Arterioscler Thromb; 1994 Mar; 14(3):483-8. PubMed ID: 8123656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monocyte tissue factor response is decreased in patients with hyperlipidemia.
    Rugeri L; Susen S; Bard JM; Corseaux D; Gavériaux V; Devos P; Lecerf JM; Duriez P; Jude B
    Thromb Res; 1999 Nov; 96(4):283-92. PubMed ID: 10593431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence that the C-terminus of tissue factor pathway inhibitor (TFPI) is essential for its in vitro and in vivo interaction with lipoproteins.
    Valentin S; Nordfang O; Bregengård C; Wildgoose P
    Blood Coagul Fibrinolysis; 1993 Oct; 4(5):713-20. PubMed ID: 8292720
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins.
    Marcoux C; Tremblay M; Fredenrich A; Davignon J; Cohn JS
    Metabolism; 2001 Jan; 50(1):112-9. PubMed ID: 11172484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue factor pathway inhibitor in complex with low density lipoprotein isolated from human plasma does not possess anticoagulant function in tissue factor-induced coagulation in vitro.
    Hansen JB; Huseby KR; Huseby NE; Ezban M; Nordøy A
    Thromb Res; 1997 Mar; 85(5):413-25. PubMed ID: 9076898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody recognized the third Kunitz domain (K3) of free-form TFPI but not lipoprotein-associated forms in plasma.
    Abumiya T; Enjyoji K; Kokawa T; Kamikubo Y; Kato H
    J Biochem; 1995 Jul; 118(1):178-82. PubMed ID: 8537308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship of tissue factor pathway inhibitor activity to plasma lipoproteins and myocardial infarction at a young age.
    Moor E; Hamsten A; Karpe F; Båvenholm P; Blombäck M; Silveira A
    Thromb Haemost; 1994 Jun; 71(6):707-12. PubMed ID: 7974336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperlipidemia in coronary heart disease. 3. Evaluation of lipoprotein phenotypes of 156 genetically defined survivors of myocardial infarction.
    Hazzard WR; Goldstein JL; Schrott MG; Motulsky AG; Bierman EL
    J Clin Invest; 1973 Jul; 52(7):1569-77. PubMed ID: 4352458
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-dependent action of atorvastatin in type IIB hyperlipidemia: preferential and progressive reduction of atherogenic apoB-containing lipoprotein subclasses (VLDL-2, IDL, small dense LDL) and stimulation of cellular cholesterol efflux.
    Guerin M; Egger P; Soudant C; Le Goff W; van Tol A; Dupuis R; Chapman MJ
    Atherosclerosis; 2002 Aug; 163(2):287-96. PubMed ID: 12052475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased plasma tissue factor pathway inhibitor in women taking combined oral contraceptives.
    Harris GM; Stendt CL; Vollenhoven BJ; Gan TE; Tipping PG
    Am J Hematol; 1999 Mar; 60(3):175-80. PubMed ID: 10072106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Analysis of behaviors of plasma tissue factor and tissue factor pathway inhibitor in patients with various diseases].
    Saito M; Morishita E; Asakura H; Jokaji H; Uotani C; Kumabashiri I; Yamazaki M; Aoshima K; Matsuda T
    Rinsho Ketsueki; 1996 Sep; 37(9):794-8. PubMed ID: 8914465
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue factor pathway inhibitor activity associated with LDL is inactivated by cell- and copper-mediated oxidation.
    Lesnik P; Dentan C; Vonica A; Moreau M; Chapman MJ
    Arterioscler Thromb Vasc Biol; 1995 Aug; 15(8):1121-30. PubMed ID: 7627705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased concentration of clusterin/apolipoprotein J (apoJ) in hyperlipemic serum is paradoxically associated with decreased apoJ content in lipoproteins.
    Rull A; Martínez-Bujidos M; Pérez-Cuellar M; Pérez A; Ordóñez-Llanos J; Sánchez-Quesada JL
    Atherosclerosis; 2015 Aug; 241(2):463-70. PubMed ID: 26081122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages.
    Milosavljevic D; Griglio S; Le Naour G; Chapman MJ
    Atherosclerosis; 2001 Mar; 155(1):251-60. PubMed ID: 11223449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated plasma levels of free-form of TFPI antigen in hypercholesterolemic patients.
    Morishita E; Asakura H; Saito M; Yamazaki M; Ontachi Y; Mizutani T; Kato M; Matsuda T; Nakao S
    Atherosclerosis; 2001 Jan; 154(1):203-12. PubMed ID: 11137101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.